SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-20-257868
Filing Date
2020-09-29
Accepted
2020-09-29 16:39:59
Documents
3
Period of Report
2020-09-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d887315d8ka.htm 8-K/A 25711
2 EX-10.1 d887315dex101.htm EX-10.1 65640
3 EX-10.2 d887315dex102.htm EX-10.2 23722
  Complete submission text file 0001193125-20-257868.txt   116548
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36510 | Film No.: 201209324
SIC: 2834 Pharmaceutical Preparations